Novotech, a contract research organization (CRO) based in the Asia-Pacific, will implement Oracle’s Trial Management and Monitoring Cloud Service (TMMCS). The company said this will enable it to have the largest trial management system in the region.
This investment, which establishes Novotech as the first to implement the TMMCS in the Asia-Pacific, is the latest in a series of ongoing investments for the CRO.
The company stated its recent investments ensure regulatory compliance and integration into global studies, allowing Novotech to have the capability to present better data visibility to, in turn, improve decision-making.
In a statement, John Moller, CEO of Novotech, stated that the technology “provides a centralized trial database enabling improved access, control and governance of clinical data.”
He further stated that the system allows for functionalities like eSignatures and tools that may enable faster approvals and submissions, therefore accelerating trial implementation.
In the Asia-Pacific region, Novotech says its clinical staff employment has risen 20% over the last quarter. This growth is thought to be fueled by demand for a CRO within the region.
In addition, the CRO has recently signed 10 strategic collaborations with hospitals and research institutions within the region.